Correlation between Clinical and Immunological Variables and Humoral Response to SARS-CoV-2 Vaccination in Adult Patients with Antibody Deficiency Disorders
Bracke Manzanares, Carmen (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Miranda, Cristina (Fight AIDS and Infectious Diseases Foundation, Badalona)
González, Sandra (Fight AIDS and Infectious Diseases Foundation, Badalona)
Casas, Irma (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Cardona, Pere-Joan (Universitat Autònoma de Barcelona. Departament de Genètica i de Microbiologia)
Benítez Díaz, Rosa María (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Sopena, Nieves (Universitat Autònoma de Barcelona. Departament de Medicina)
Reynaga, Esteban (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Massanella, Marta (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa)
Clotet Sala, Bonaventura (Universitat Autònoma de Barcelona. Departament de Medicina)
Carrillo, Jorge (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa)
Mateu, Lourdes (Universitat Autònoma de Barcelona. Departament de Medicina)
Pedro-Botet Montoya, Maria Luisa (Universitat Autònoma de Barcelona. Departament de Medicina)

Data:	2022
Resum:	Background. Prophylactic vaccination has proven to be the most effective strategy to fight the COVID-19 pandemic. Methods. This was a prospective observational cohort study involving 30 predominantly antibody deficiency disorders (ADD)-afflicted adult patients on immunoglobulin replacement therapy vaccinated with three doses of the mRNA-1273 COVID-19 vaccine, and 10 healthy controls. Anti-RBD IgG antibodies were determined in plasma samples collected just before the first dose of mRNA-based COVID-19 vaccine and on weeks 4, 8, 24, and 28 following the first vaccination. Patients were categorized based on the levels of anti-RBD antibodies determined on w8 as non-, low-, and responders. Chi-square and Kruskal-Wallis tests were used to see if any variables correlated with humoral response levels. Any adverse effects of the mRNA-based vaccine were also noted. Results. The COVID-19 vaccine was safe and well-tolerated. The humoral response elicited at w8 after vaccination depended on the type of ADD, the type of immunoglobulin deficiency, the presence of granulomatous lymphocytic interstitial lung disease, recent use of immunosuppressive drugs, and the switched memory B cells counts. The third vaccine dose boosted humoral response in previous responders to second dose but seldom in non-responders. Conclusions: The humoral response of patients with predominant ADD depends mostly on the type of immunodeficiency and on the frequency of B and T cell populations.
Nota:	Altres ajuts: Generalitat de Catalunya's Department de salut (SLD015); Consorcio Centro de Investigación Biomédica en Red (CB-2021)
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	COVID-19 vaccination ; Antibody deficiency disorders ; Primary immunodeficiencies ; Secondary immunodeficiencies ; COVID-19 vaccination response ; GLILD ; Immunosuppressive therapy
Publicat a:	Pathogens, Vol. 11 (november 2022) , ISSN 2076-0817

DOI: 10.3390/pathogens11111364
PMID: 36422615

12 p, 481.5 KB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Articles > Articles de recerca
Articles > Articles publicats